SECAUCUS, N.J., May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 11:00 a.m. Eastern Time.The presentation session will be webcast live during the conference on the company's ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks ...

Quest Diagnostics Inc. (DGX) is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company also strategizes to generate growth through value-creating, strategically aligned acquisitions using disciplined investment criteria. Efforts to drive operational excellence are also encouraging. Meanwhile, escalating debt levels and intense competitive space raise concerns for Quest Diagnostics’ operations.In the past year, this Zacks Rank #3 (Ho ...

Core Insights - The report titled "The Cancer Paradox" reveals that oncologists are increasingly encountering advanced-stage cancers, attributing this trend primarily to screening barriers and other factors [3][4][5] - The report highlights the need for improved post-treatment monitoring tools, particularly the emerging ctDNA minimal residual disease (MRD) blood tests, which could enhance early detection of cancer recurrence [3][4][8] Group 1: Oncologists' Perspectives - 76% of oncologists report seeing more advanced-stage cancers, with 75% citing screening barriers as the main cause, followed by aging population (48%) and lifestyle factors (43%) [4][5] - 68% of oncologists believe missed or delayed follow-up care is a significant reason for missed cancer recurrence, while 50% point to imaging tests failing to detect recurrence early enough [5][13] - 94% of oncologists agree that ctDNA MRD testing could reduce delays in diagnosing cancer recurrence, although they face barriers to its widespread adoption [5][8] Group 2: Limitations of Current Monitoring Methods - Traditional methods for monitoring cancer recurrence, such as PET scans and MRIs, are viewed as expensive and invasive, with 50% of oncologists noting that imaging tests often fail to detect recurrence early [6][7] - Nearly all oncologists (96%) believe MRD testing can identify cancer recurrence earlier than current methods, with 89% emphasizing the importance of test sensitivity [7][8] Group 3: Adoption of ctDNA MRD Testing - 88% of oncologists support incorporating MRD testing into standard care for cancer-recurrence monitoring, but over half would be more inclined to recommend it with more clinical evidence, inclusion in clinical guidelines, and better insurance coverage [8][9] - A study published in NEJM found that the Haystack MRD test was a reliable alternative to tissue biopsies, identifying complete responses to immunotherapy faster than traditional imaging methods [9] Group 4: Oncologists' Challenges - 89% of oncologists believe early detection of cancer recurrence can improve outcomes, yet 79% report seeing patients whose recurrence was missed at earlier stages [13] - Anxiety and worry are cited as significant challenges for patients, with 87% of oncologists acknowledging this concern, compared to 53% who mention treatment side effects [13]

Quest Diagnostics (NYSE: DGX ) is a leader in the diagnostics industry. I believe it leads in scale, scope and quality of service compared to its peers. It also commands economies of scale due to its market leadershipI am currently working as an investment analyst at a family office. My specialty is identifying high-quality and/or severely mispriced investment ideas. I believe that a great investment idea would "jump" at you intuitively and it comes in buying great companies at great prices. If you like my ...

Financial Performance - Net revenues for the three months ended March 31, 2025, increased by 12.1% to $2,652 million compared to $2,366 million in the prior year period [114]. - Operating income for the three months ended March 31, 2025, was $346 million, a 15.4% increase from $300 million in the prior year [114]. - Net income attributable to Quest Diagnostics increased by 13.2% to $220 million, with diluted earnings per share rising to $1.94 from $1.72 [114][121]. Revenue Drivers - Diagnostic Information Services (DIS) revenues rose by 12.7% to $2,589 million, driven primarily by recent acquisitions contributing approximately 10.0% to DIS revenues [122][133]. - Requisition volume increased by 12.4%, with organic volume down by 0.9%, while revenue per requisition increased by 0.3% [114][133]. Cost and Expenses - Cost of services increased by $194 million, primarily due to recent acquisitions and wage increases, partially offset by cost savings from the Invigorate program [126]. - Selling, general and administrative expenses (SG&A) rose by $36 million, mainly driven by the impact of recent acquisitions [128]. - The Invigorate program aims to deliver 3% annual cost savings and productivity improvements to offset inflationary pressures [115]. Tax and Charges - The effective income tax rate decreased to 21.5% from 25.0%, benefiting from excess tax benefits associated with stock-based compensation arrangements [136]. - The company incurred $19 million in pre-tax charges related to restructuring and integration activities during the quarter [116]. Cash Flow and Investments - The company reported a net cash provided by operating activities of $314 million for the three months ended March 31, 2025, an increase of $160 million compared to $154 million in the same period of 2024 [149]. - Net cash used in investing activities decreased to $115 million for the three months ended March 31, 2025, from $213 million in the prior year, primarily due to reduced cash used for business acquisitions [151]. - Net cash used in financing activities increased to $561 million for the three months ended March 31, 2025, compared to $153 million in the same period of 2024, mainly due to the repayment of $600 million of senior notes [152]. Debt and Borrowing - As of March 31, 2025, the estimated fair value of the company's debt was approximately $5.8 billion, down from $6.1 billion as of December 31, 2024, with a fair value less than the carrying value by $59 million [139]. - The company had $1.1 billion of borrowing capacity available under existing credit facilities as of March 31, 2025, including $308 million under the secured receivables credit facility [164]. - As of March 31, 2025, the company had $215 million of borrowings outstanding under the secured receivables credit facility and no borrowings under the senior unsecured revolving credit facility [140]. Dividends and Shareholder Returns - The company declared a quarterly cash dividend of $0.80 per common share during the first quarter of 2025, up from $0.75 per share in each quarter of 2024 [155]. Operational Efficiency - Days sales outstanding improved to 47 days as of March 31, 2025, down from 50 days as of March 31, 2024, indicating enhanced billing and collection efficiency [150]. - The company is committed to a multi-year project ("Project Nova") aimed at modernizing its "Order-to-Cash" business processes, which is expected to deliver operational benefits and improve customer experience [163]. Capital Expenditures - The company expects to invest approximately $500 million in capital expenditures during 2025 to support and grow existing operations, particularly in laboratory equipment and facilities [162]. Interest Rate Swaps - The notional amount of fixed-to-variable interest rate swaps was $1.25 billion as of March 31, 2025, with an aggregate fair value in a liability position of $6 million [141]. - The fair value of fixed-to-variable interest rate swaps was $6 million in a liability position as of March 31, 2025, down from $34 million as of December 31, 2024 [141].

Core Insights - Quest Diagnostics Incorporated reported better-than-expected first-quarter earnings with earnings of $2.21 per share, surpassing the analyst consensus estimate of $2.15 per share [1] - The company achieved quarterly sales of $2.65 billion, exceeding the analyst consensus estimate of $2.63 billion [1] Financial Performance - In the first quarter, Quest Diagnostics experienced strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, attributed to demand recovery in March [2] - The growth was driven by contributions from acquisitions, large enterprise accounts, demand for advanced diagnostics, and expanded health plan access [2] - The company reaffirmed its 2025 revenue guidance of $10.70 billion to $10.85 billion, compared to the consensus of $10.78 billion, and adjusted EPS guidance of $9.55 to $9.80, against the consensus of $9.68 [2] Stock Performance - Following the earnings announcement, Quest Diagnostics shares fell 0.1% to trade at $172.71 [3] - Analysts adjusted their price targets for Quest Diagnostics after the earnings report [3] Analyst Ratings - Baird analyst Eric Coldwell maintained an Outperform rating and raised the price target from $191 to $194 [7] - Evercore ISI Group analyst Elizabeth Anderson maintained an In-Line rating and increased the price target from $175 to $180 [7] - Barclays analyst Stephanie Davis maintained an Equal-Weight rating and raised the price target from $175 to $185 [7] - Truist Securities analyst David Macdonald maintained a Hold rating and increased the price target from $182 to $190 [7]

Core Viewpoint - Quest Diagnostics Inc reported strong first-quarter 2025 results, with sales and adjusted earnings exceeding consensus estimates, indicating robust demand and effective management strategies [1][2][4]. Financial Performance - First-quarter 2025 sales reached $2.65 billion, a 12.1% increase year over year, surpassing the consensus of $2.63 billion [1]. - Adjusted earnings per share (EPS) were $2.21, up 8.3%, beating the consensus of $2.15 [1]. - Adjusted operating income increased by 16.3% to $406 million, with operating margin improving from 14.8% to 15.3% [3]. Growth Drivers - The revenue growth was attributed to nearly 2.5% organic growth, contributions from acquisitions, demand for advanced diagnostics, and expanded health plan access [2]. - Requisition volume increased by 12.4%, while revenue per requisition rose by 0.3% [3]. Guidance and Outlook - The company reaffirmed its 2025 revenue guidance of $10.70 billion to $10.85 billion, compared to the consensus of $10.78 billion, and adjusted EPS guidance of $9.55 to $9.80, against a consensus of $9.68 [4]. - The acquisition of select assets from Fresenius Medical Care AG is expected to close in the second half of 2025, with service transitions anticipated to complete by early 2026 [4][5]. Strategic Initiatives - Quest Diagnostics will provide comprehensive laboratory services related to end-stage kidney disease for Fresenius Medical Care's dialysis centers [5]. - A partnership with GRAIL Inc. aims to enhance provider access to the Galleri multi-cancer early detection test through Quest's connectivity system [6]. Market Position - Analysts view the results as consistent with expectations, highlighting the company's resilience against macroeconomic factors and a favorable regulatory environment [7][8]. - Quest Diagnostics stock rose by 7.83% to $174.53 following the announcement [8].

Financial Data and Key Metrics Changes - In Q1 2025, consolidated revenues were $2.65 billion, up 12.1% year-over-year, with organic revenues growing by 2.4% [28] - Reported operating income was $346 million, representing 13% of revenues, compared to $300 million or 12.7% of revenues last year [31] - Reported EPS was $1.94, compared to $1.72 a year ago, while adjusted EPS was $2.21 versus $2.04 the prior year [32] Business Line Data and Key Metrics Changes - Revenues for Diagnostic Information Services increased by 12.7% year-over-year, driven by acquisitions and growth in physician and hospital channels [29] - Total volume measured by requisitions increased by 12.4% year-over-year, with organic volume down by 0.9% [29] - Revenue per requisition was up 0.3% year-over-year, with organic revenue per requisition increasing by 3.6% [30] Market Data and Key Metrics Changes - The physician channel saw revenue growth in the high teens, largely driven by acquisitions, with organic revenue growth in the mid-single digits [13] - Advanced diagnostics in key clinical areas such as cardiometabolic and autoimmune testing grew at double-digit rates [20] - The company expanded its health plan partnerships, contributing to revenue growth through access to new geographies [14] Company Strategy and Development Direction - The company’s growth strategy focuses on delivering solutions for core clinical customers and expanding into consumer-initiated testing, life sciences, and data analytics [11] - Automation, robotics, and AI are being deployed to improve quality and productivity [12] - The company aims to expand in high-growth areas and enhance its online consumer-initiated test platform [18] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed revenue and adjusted EPS guidance for the full year 2025, expecting revenues between $10.7 billion and $10.85 billion [33] - The company anticipates approximately 3% organic revenue growth, with the remainder from acquisitions [35] - Management expressed optimism regarding the impact of recent regulatory changes and ongoing investments in quality management processes [10][36] Other Important Information - The company is collaborating with Google Cloud to streamline data management and enhance customer and employee experiences through GenAI [26] - The recent court ruling vacating the FDA rule on laboratory developed tests is expected to reduce regulatory costs and improve access to innovative testing services [9][10] Q&A Session Summary Question: Organic volume trends and expectations for the rest of the year - Management noted that organic volume was down 90 basis points but would have increased by 160 basis points when adjusting for leap year and weather impacts [42][43] Question: Exposure to tariffs and supply costs - Management indicated that less than 1% of their $2 billion supply spend is sourced directly from China, with most supplies manufactured in the U.S. [48][50] Question: Impact of strikes at LifeLabs - Management clarified that the strike is limited to British Columbia and is being managed effectively, with progress expected in the next 30 to 45 days [56][57] Question: Margin expectations for Q2 - Management expects Q2 to be the strongest quarter, with operating margins anticipated to grow compared to the previous year [60][62] Question: Opportunities in hospital lab management due to tariffs - Management indicated that the funnel of opportunities in collaborative lab services remains robust, with ongoing negotiations with several institutions [72] Question: Updates on Haystack and reimbursement submissions - Management reported positive progress with Haystack, with ongoing efforts to establish reimbursement processes [95][96] Question: Financial benefits from collaboration with Google Cloud - Management highlighted that moving data to the cloud will improve efficiency in data analytics and enhance customer and employee experiences [102][104] Question: Regulatory updates and potential cuts to Medicare and Medicaid - Management expressed optimism regarding Medicare Advantage rate increases and is closely monitoring potential Medicaid cuts, which represent about 8% of their business [107][110]

Core Viewpoint - Quest Diagnostics Inc. reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of $2.21, exceeding estimates and showing year-over-year growth [1][2][8] Financial Performance - Adjusted EPS of $2.21 beat the Zacks Consensus Estimate by 2.8% and increased by 8.3% compared to the previous year [1] - GAAP EPS was $1.94, reflecting a 12.8% increase from the same quarter last year [2] - Revenues rose 12.1% year over year to $2.65 billion, surpassing the Zacks Consensus Estimate by 1.5% [3] - Diagnostic Information Services revenues increased by 12.7% year over year to $2.59 billion, exceeding projections [3] - Volumes measured by requisitions were up 12.5% year over year, with revenue per requisition increasing by 0.3% [4] Margin and Cost Analysis - Cost of services was $1.79 billion, up 12.2% year over year, while gross profit reached $863 million, an 11.9% increase [5] - Gross margin stood at 32.5%, nearly unchanged from the previous year [5] - SG&A expenses were $476 million, an 8.1% increase from the first quarter of 2024 [5] - Adjusted operating margin improved by 60 basis points year over year to 14.6% [5] Liquidity and Financial Health - Cash and cash equivalents at the end of Q1 2025 were $188 million, down from $549 million at the end of Q4 2024 [6] - Cumulative net cash from operating activities was $314 million, compared to $154 million at the same time last year [6] - The company has a five-year annualized dividend growth rate of 7.17% [6] 2025 Guidance - Full-year 2025 revenue outlook is reaffirmed at $10.70 billion to $10.85 billion, indicating a year-over-year increase of 8.4% to 9.9% [7] - Adjusted EPS guidance remains unchanged at $9.55 to $9.80, with the Zacks Consensus Estimate at $9.68 [7] Market Reaction and Outlook - Following the earnings report, DGX shares gained nearly 6.7% in pre-market trading [2] - The growth in revenue was attributed to a rebound in demand, contributions from acquisitions, and expanded health plan access [8][9]